To explore the effects of glucagon-like peptide-1 therapy (GLP-1) on the expression of growth different factor 15 (GDF15) in hepatocytes of metabolic dysfunction-associated fatty liver disease (MAFLD). Patients with MAFLD and type 2 diabetes mellitus received a 26-week therapy of liraglutide, sitagliptin, or insulin glargine, respectively. The level of serum GDF15, intrahepatic lipid (IHL) and body mass index (BMI) were collected at baseline and week 26. C57BL/6J mice challenged with a high-fat diet (HFD) for 12 weeks were treated with GLP-1 receptor agonist exenatide (GLP-1 group) or normal saline by intraperitoneal injection for 8 weeks (HFD group). Another group with a chow diet was designed as normal control. Human HepG2 cells were incubated in medium containing 300 μM sodium palmitate (PA) and treated with Exendin-4 0nM, 1 nM, 20 nM, 100 nM, respectively. A total of 25 patients were analyzed (liraglutide group, 9; insulin glargine group, 8 and sitagliptin group, 8). The level of serum GDF15 increased significantly in the liraglutide group (742±279pg/mL vs. 920±265pg/mL, P=0.015), and IHL and BMI decreased significantly (18.3±7.4% vs. 12.2±5.5%, P=0.004; 29.0±2.2kg/m2 vs. 27.8±1.9 kg/m2, P= 0.01, respectively). No significant changes in the level of serum GDF15 were observed in the sitagliptin and insulin glargine groups after 26-week therapy. Furthermore, negative correlation was found between the change in serum GDF15 and IHL by in the liraglutide group (r=-0.676, P=0.045). Hepatic steatosis and inflammation in the liver, which were improved markedly in the HFD group, reduced in GLP-1 group. Relative mRNA levels of GDF15 in liver tissue of mice were remarkably higher in the GLP-1 group than those in HFD group and control group (P<0.05). In addition, Exendin-4 alleviated lipid deposition in HepG2 cells, which induced by PA, and elevate the expression and secretion of GDF15 in a dose-dependent manner (P<0.05). GLP-1 can alleviates hepatic steatosis of MAFLD and up-regulate the expression and secretion of GDF15.

Disclosure

L. Gan: None. B. Lin: None. W. Xu: None. J. Yan: None. Y. Su: None. Y. Chen: None. D. Yang: None. H. Liang: None. F. Xu: None.

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.